Labcorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
The patient's age, gender, height, and weight at the time of collection must be submitted for FibroSure® testing.
3 - 6 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Red-top tube or gel-barrier tube
Separate serum from cells within two hours of collection.
Specimen can be stored refrigerated at 2°C to 8°C for 72 hours and frozen at -70°C for seven days. Frozen samples are stable for one freeze/thaw cycle.
Patient should be fasting for at least eight hours.
Gross hemolysis; gross lipemia; improper labeling; nonfasting specimen; patient younger than 14 years of age
This test is a noninvasive assessment of liver status in patients with nonalcoholic fatty liver disease (NAFLD). Quantitative results of 10 biochemicals in combination with age, gender, height, and weight are analyzed using a computational algorithm to provide a quantitative surrogate marker (0.0-1.0) of liver fibrosis (Metavir F0-F4), hepatic steatosis (0.0-1.0, S0-S3), and nonalcoholic steatohepatitis (NASH) (0.0-0.75, N0-N2). The absence of steatosis (S<0.38) precludes the diagnosis of NASH.
NASH FibroSure® is recommended for patients with suspected nonalcoholic fatty liver disease. It is not recommended for patient with other liver diseases. It is also not recommended in patients with Gilbert disease, acute hemolysis, acute hepatitis, acute inflammation of the liver, autoimmune hepatitis, extrahepatic cholestasis, transplant patients, and/or renal insufficiency patients. Any of these clinical situations may lead to inaccurate quantitative predictions of fibrosis.
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|550140||NASH FibroSure||550147||Fibrosis Score||48795-9|
|550140||NASH FibroSure||550148||Fibrosis Stage||48794-2|
|550140||NASH FibroSure||550149||Steatosis Score||N/A|
|550140||NASH FibroSure||550153||Steatosis Grade||N/A|
|550140||NASH FibroSure||550157||NASH Score||48792-6|
|550140||NASH FibroSure||550142||NASH Grade||48793-4|
|550140||NASH FibroSure||122137||Alpha 2-Macroglobulins, Qn||mg/dL||1835-8|
|550140||NASH FibroSure||016874||Apolipoprotein A-1||mg/dL||1869-7|
|550140||NASH FibroSure||001100||Bilirubin, Total||mg/dL||1975-2|
|550140||NASH FibroSure||001547||ALT (SGPT) P5P||IU/L||1743-4|
|550140||NASH FibroSure||001125||AST (SGOT) P5P||IU/L||30239-8|
|550140||NASH FibroSure||001067||Cholesterol, Total||mg/dL||2093-3|
|550140||NASH FibroSure||001036||Glucose, Serum||mg/dL||2345-7|
|550140||NASH FibroSure||550107||Fibrosis Scoring:||N/A|
|550140||NASH FibroSure||550189||Steatosis Grading||N/A|
|550140||NASH FibroSure||550144||NASH Scoring||N/A|
© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf